摘要
目的观察在经皮冠状动脉介入治疗(PCI)患者中硫酸氯吡格雷抵抗的发生情况。评价p-选择素与氯吡格雷抵抗发生率的相关性,并进一步探讨氯吡格雷抵抗与CD62p的关联性。方法 86名接受PCI治疗的患者在服用氯吡格雷前及一月后抽血,利用比浊法测定ADP诱导的血小板最大聚集率(PAGM),同时用流式细胞术测定CD62p。根据PAGM降低程度判断氯吡格雷抵抗发生率。结果 86例给予氯吡格雷300mg负荷量并行PCI患者发生氯吡格雷抵抗者为22例(25.4%)。CD62p与PAGM具有正相关。结论 PCI介入治疗的患者中存在部分氯吡格雷抵抗者。CD62p与PGAM相关,且百分比相比更具有意义。氯吡格雷抵抗可用CD62p的下降程度来界定。
Objective To observe the percutaneous coronary intervention （PCI） in patients with clopidogrel resistance happened. The purpose is to evaluate the incidence of clopidogrel resistance of the relevance, and to further explore the relevance of CD62P and clopidogrel resistance. Methods Taking the clopidogrel before and after 30days, 86 patients who receive PC] are blooded. Turbidimetry detect maximum platelet aggregation（PAGM） ,which use ADP-induced. Meanwhile, we use the flow Cytometry （FCM） to detect CD62p. According to the extent of the PAGM reducing, we judge the incidence of clopidogrel resistance. Results Clopidogrel resistance has occurred in 22 patients （25.4%） in PCI patients. CD62p and PAGM are positively correlated. Conclusion To some patients, there are clopidogrel resisters in PCI. CD62p relates with PGAM. Furthermore, percentages are more meaningful. Clopidogrel resistance can be defined by the extent of CD62p.
出处
《中国老年保健医学》
2012年第4期15-18,共4页
Chinese Journal of Geriatric Care
